Tyrosine Kinase Inhibitors and Cancer Therapy
作者： Srinivasan Madhusudan , Trivadi S. Ganesan
DOI: 10.1007/978-3-540-31209-3_3
关键词:
摘要: Cancer is the second leading cause of death in western world and an increasing health problem developing world. Overall survival patients with advanced cancer poor. Until recently, surgery, chemotherapy, radiotherapy endocrine therapy have been mainstay treatment patients. This has improved outcomes certain tumour types but treatment-related toxicity emergence drug resistance major morbidity mortality. need to improve stimulated intense scientific research recent years. Several novel targets identified. Amongst these, tyrosine kinases emerged as new promising anti-cancer target. Inhibitors BCR-ABL, EGFR VEGFR now licenced for use cancers. In this chapter, we will discuss how achieved
springer.com
sci-hub.st 参考文章(213)
R. Sadasivan, R. Morgan, S. Jennings, M. Austenfeld, P. Van veldhuizen, R. Stephens, M. Noble, Overexpression of Her-2/Neu may be an Indicator of Poor Prognosis in Prostate Cancer The Journal of Urology. ,vol. 150, pp. 126- 131 ,(1993) , 10.1016/S0022-5347(17)35413-7
A Zaczek, K P Bielawski, B Brandt, The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histology and Histopathology. ,vol. 20, pp. 1005- 1015 ,(2005) , 10.14670/HH-20.1005
G. H. Sato, J. Mendelsohn, J. Polikoff, J. D. Sato, A. D. Le, T. Kawamoto, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine. ,vol. 1, pp. 511- 529 ,(1983)
Joan Albanell, Jordi Codony, Ana Rovira, Begoña Mellado, Pere Gascón, Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4 Advances in Experimental Medicine and Biology. ,vol. 532, pp. 253- 268 ,(2003) , 10.1007/978-1-4615-0081-0_21
Mark D. Pegram, Gottfried Konecny, Angela Lopez, Dennis J. Slamon, Trastuzumab and chemotherapeutics: drug interactions and synergies. Seminars in Oncology. ,vol. 27, pp. 21- 25 ,(2000)
Randy D. Gascoyne, Patricia Aoun, Daniel Wu, Mukesh Chhanabhai, Brian F. Skinnider, Timothy C. Greiner, Stephan W. Morris, Joseph M. Connors, Julie M. Vose, David S. Viswanatha, Andrew Coldman, Dennis D. Weisenburger, Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma Blood. ,vol. 93, pp. 3913- 3921 ,(1999) , 10.1182/BLOOD.V93.11.3913.411K22_3913_3921
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
Alan Wells, Tumor Invasion: Role of Growth Factor-Induced Cell Motility Advances in Cancer Research. ,vol. 78, pp. 31- 101 ,(1999) , 10.1016/S0065-230X(08)61023-4
Heike Allgayer, Douglas D. Boyd, Markus M. Heiss, Eddie K. Abdalla, Steven A. Curley, Gary E. Gallick, Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. ,vol. 94, pp. 344- 351 ,(2002) , 10.1002/CNCR.10221
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381